NKTR

Nektar Therapeutics

Nektar Therapeutics Reports First Quarter 2026 Financial Results Nektar Therapeutics Reports First Quarter 2026 Financial Results PR Newswire SAN FRANCISCO, May 7, 2026 SAN FRANCISCO, May 7, 2026...

NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds...

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2026 in Nektar Therapeutics Lawsuit - NKTR The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May...

NKTR Deadline: NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit NKTR Deadline: NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit PR Newswire NEW YORK, May 4, 2026 NEW YORK, May 4, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a...

The Law Offices of Frank R. Cruz reminds investors of the upcoming May 5, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors...

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eleven ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating an...

Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to...

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with...

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN FRANCISCO, May 1...